For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
9
views
12
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
2 collections
    0
    shares
      572
      similar
       All similar

      Call for Papers: Digital Diagnostic Techniques

      Submit here before November 30, 2024

      About Pathobiology: 3.5 Impact Factor I 8.5 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind

      case-report
      Author(s): ,
      Publication date (Electronic):
      Journal: Case Reports in Oncology
      Publisher: S. Karger AG
      Keywords: Capecitabine, Vision loss, Antineoplastic agents, Rectal cancer, Toxicity

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Capecitabine is an orally administered fluoropyrimidine carbamate antineoplastic agent, widely used to treat different tumor types. Eye toxicity is not well established with this type of drug. Here, we report the case of a 57-year-old man with a low rectal cancer whose vision decreased 3 weeks after starting a daily treatment of capecitabine and radiotherapy. After eliminating all other diagnoses, toxicity of antineoplastic agents remains the most likely hypothesis, making it the first case of vision loss induced by this capecitabine.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: not found

          The role of pharmacogenetics in capecitabine efficacy and toxicity

          H.J. Guchelaar, S.W. Lam, E Boven (2016)
          Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients. In this review we present the current knowledge on genetic variants, commonly single-nucleotide polymorphisms (SNPs), tested in cohorts of cancer patients and possibly useful for prediction of capecitabine efficacy or toxicity. Capecitabine is activated to 5-FU by CES, CDA and TYMP, of which SNPs in CDA and CES2 were found to be associated with efficacy and toxicity. In addition, variants in genes of the 5-FU metabolic pathway, including TYMS, MTHFR and DPYD also influenced capecitabine efficacy and toxicity. In particular, well-known SNPs in TYMS and DPYD as well as putative DPYD SNPs had an association with clinical outcome as well as adverse events. Inconsistent findings may be attributable to factors related to ethnic differences, sample size, study design, study endpoints, dosing schedule and the use of multiple agents. Of the SNPs described in this review, dose reduction of fluoropyrimidines based on the presence of DPYD variants *2A (rs3918290), *13 (rs55886062), -2846A>T (rs67376798) and -1236G>A/HapB3 (rs56038477) has already been recommended. Other variants merit further validation to establish their definite role in explanation of interindividual differences in the outcome of capecitabine-based therapy.
          Article 0 comments Cited 43 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Oral Anti-Vascular Endothelial Growth Factor Drugs and Ocular Adverse Events.

            Frederick Fraunfelder, Frederick Fraunfelder (2018)
            To evaluate possible associations between oral anti-vascular endothelial growth factor (VEGF) drugs and ocular side effects.
            Article 0 comments Cited 14 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics.

              Anne L. Kunkler, Elaine Binkley, Dimosthenis Mantopoulos … (2019)
              Increases in cancer with an aging population and the rapid development of new chemotherapeutics underscore the need for ophthalmologists to identify and manage potential ocular toxicities. This retrospective case series reports the ocular side effects of traditional and novel chemotherapeutic agents from a large center.
              Article 0 comments Cited 13 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Case Rep Oncol
                Journal ID (iso-abbrev): Case Rep Oncol
                Journal ID (hwp): CRO
                Journal ID (publisher-id): CRO
                Title: Case Reports in Oncology
                Publisher: S. Karger AG (Basel, Switzerland )
                ISSN (Electronic): 1662-6575
                Publication date (Electronic): 3 July 2023
                Publication date Collection: Jan-Dec 2023
                Publication date PMC-release: 3 July 2023
                Volume: 16
                Issue: 1
                Pages: 474-477
                Affiliations
                [1]Digestive Oncology Department, Institut Gustave Roussy, Villejuif, France
                Author notes
                Correspondence to: Paul Matte, paul.matte@ 123456hotmail.fr
                Article
                Publisher ID: 530402
                DOI: 10.1159/000530402
                PMC ID: 10368103
                PubMed ID: 37497421
                SO-VID: 64128cb3-68bd-45bf-ab30-565c7f19293a
                Copyright © © 2023 The Author(s). Published by S. Karger AG, Basel
                License:

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

                History
                Date received : 2 November 2022
                Date accepted : 22 March 2023
                Date: 2023
                Page count
                References: 12, Pages: 4
                Funding
                This study did not receive any funding.
                Categories
                Subject: Case Report

                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: capecitabine,vision loss,antineoplastic agents,rectal cancer,toxicity
                Data availability:
                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: capecitabine, vision loss, antineoplastic agents, rectal cancer, toxicity

                Comments

                Comment on this article

                scite_

                Similar content572

                See all similar

                Cited by1

                See all cited by

                Most referenced authors141

                See all reference authors